antwerpes AG

euro adhoc: DocCheck AG
quarterly or semiannual financial statement
DocCheck has achieved an increase in sales of 15 % in the 2nd quarter

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

6-month report

06.08.2007

Cologne, 6 August 2007 - In the 2nd quarter of 2007 DocCheck AG, Cologne, (ISIN DE0005471007 //Symbol 547100) has achieved sales totalling 3.5 million euro. This corresponds to an increase of 15 per cent when compared to the 2nd quarter of 2006 (3.0 million euro). The operating result turned out to be negative (- 106 thousand euro) and fell below the result for the same period in the previous year (+ 87 thousand euro). The result per share is 0 cent (previous year: 2 cent). Overall DocCheck AG's sales have increased by 10 per cent in the first six months of 2007, rising from 6.2 million euro to 6.8 million euro. Earnings before interest and taxes (EBIT) total - 67 thousand euro (previous year: 415 thousand euro), profit per share is 1 cent (previous year: 7 cent). Liquid funds and current-asset securities amounted to 14.9 million euro at the end of the 2nd quarter or 2.53 euro per share (previous year: 16.0 million euro or 2.70 euro per share), due, amongst other things, to the payment of dividends on 28/06/2007 totalling 570 thousand euro, share buy-backs (272 thousand euro) and investments in additional office space (300 thousand euro). The 2nd quarter for the DocCheck Group was marked by a dynamic increase in the portal and trading business on the one hand and lower customer budgets in the agency business on the other hand. As already announced at publication of the 1st quarter´s results, some customers had reduced their marketing expenditure at the beginning of the year as a result of the changes to the prevailing statutory conditions caused by major health care reforms and the ensuing slight decline in the pharmaceutical market. As expected, sales in the agency business (antwerpes + partner) subsequently dropped by 3 per cent to 1.3 million euro in the 2nd quarter. The portal business continued to increase at a rapid pace in terms of development and investments and sales increased by 15 per cent to 0.8 million euro. Development in the 2nd quarter concentrated on the development of DocCheck-Faces, a social network software package for doctors which will appear in its final version as DocCheck-Service during the 3rd quarter. Sales in the trading business (DocCheck Shop) increased by 49 per cent to 1.5 million euro. The outlook for the 3rd quarter is positive. At the beginning of the 3rd quarter incoming orders in the agency business increased sharply, as reflected in the orders on the books. In particular the demand for integrated concepts in e-marketing, Print and PR has increased and a number of new budgets have been acquired. At the same time the portal and trading business is developing according to plan. Due to the healthy business outlook, the board of directors is expecting a positive operating result for the 3rd quarter with an increase in sales.

@@start.t2@@end of announcement                                                 euro adhoc 06.08.2007 22:00:00
--------------------------------------------------------------------------------@@end@@

ots Originaltext: antwerpes AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Tanja Mumme
+49 (0)221 92053 139
tanja.mumme@doccheck.com

Branche: Computing & Information Technology
ISIN:      DE0005471007
WKN:        547100
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse München / free trade



Weitere Meldungen: antwerpes AG

Das könnte Sie auch interessieren: